CTX-0294885 | Broad-spectrum Kinase Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / CTX-0294885

CTX-0294885 {[allProObj[0].p_purity_real_show]}

货号：A173517

CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen.

CTX-0294885 化学结构
CAS号：1439934-41-4

CTX-0294885 3D分子结构
CAS号：1439934-41-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

CTX-0294885 纯度/质量文件产品仅供科研

货号：A173517 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

Aurora Kinase 亚型比较
FLT3 亚型比较
FAK 亚型比较
JAK 亚型比较
VEGFR 亚型比较

产品名称	Aurora A ↓ ↑	Aurora B ↓ ↑	Aurora C ↓ ↑	其他靶点	纯度
BI-847325	++ Aurora A (Human), IC50: 25 nM	++++ Aurora B (Xenopus laevis), IC50: 3 nM	++ Aurora C (Human), IC50: 15 nM		{[allProObj[0].p_purity_real_show]}
CCT 137690	++ Aurora A, IC50: 15 nM	++ Aurora B, IC50: 25 nM	++ Aurora C, IC50: 19 nM		{[allProObj[0].p_purity_real_show]}
MK-5108	++++ Aurora A, IC50: 0.064 nM				{[allProObj[0].p_purity_real_show]}
KW-2449	+ Aurora A, IC50: 48 nM			FLT3	{[allProObj[0].p_purity_real_show]}
Tozasertib	++++ Aurora A, Ki app: 0.6 nM	++ Aurora B, Ki app: 18 nM	+++ Aurora C, Ki app: 4.6 nM	FLT3,Bcr-Abl	{[allProObj[0].p_purity_real_show]}
AT9283	++++ Aurora A, IC50: ~3.0 nM	++++ Aurora B, IC50: ~3.0 nM			{[allProObj[0].p_purity_real_show]}
MLN8054	+++ Aurora A, IC50: 4 nM	+ Aurora B, IC50: 172 nM			{[allProObj[0].p_purity_real_show]}
ZM-447439	+ Aurora A, IC50: 110 nM	+ Aurora B, IC50: 130 nM		Src	{[allProObj[0].p_purity_real_show]}
TCS7010	++++ Aurora A, IC50: 3.4 nM				{[allProObj[0].p_purity_real_show]}
TAK-901	++ Aurora A-TPX2, IC50: 21 nM	++ Aurora B-INCENP, IC50: 15 nM			{[allProObj[0].p_purity_real_show]}
Danusertib	+++ Aurora A, IC50: 13 nM	+ Aurora B, IC50: 79 nM	+ Aurora C, IC50: 61 nM	RET	{[allProObj[0].p_purity_real_show]}
MK-8745	++++ Aurora A, IC50: 0.6 nM				{[allProObj[0].p_purity_real_show]}
PHA-680632	++ Aurora A, IC50: 27 nM	+ Aurora B, IC50: 135 nM	+ Aurora C, IC50: 120 nM	FLT3	{[allProObj[0].p_purity_real_show]}
AMG 900	+++ Aurora A, IC50: 5 nM	+++ Aurora B, IC50: 4 nM	++++ Aurora C, IC50: 1 nM		{[allProObj[0].p_purity_real_show]}
Alisertib	++++ Aurora A, IC50: 1.2 nM				{[allProObj[0].p_purity_real_show]}
ENMD-2076	+++ Aurora A, IC50: 14 nM	+ Aurora B, IC50: 350 nM		RET,FLT3	{[allProObj[0].p_purity_real_show]}
JNJ-7706621	+++ Aurora A, IC50: 11 nM	++ Aurora B, IC50: 15 nM			{[allProObj[0].p_purity_real_show]}
CYC-116	+++ Aurora A, Ki: 8 nM	+++ Aurora B, Ki: 9 nM		FLT3	{[allProObj[0].p_purity_real_show]}
Reversine	+++ Aurora A, IC50: 12 nM	+++ Aurora B, IC50: 13 nM	++ Aurora C, IC50: 20 nM		{[allProObj[0].p_purity_real_show]}
CCT129202	++ Aurora A, IC50: 42 nM	+ Aurora B, IC50: 198 nM	+ Aurora C, IC50: 227 nM		{[allProObj[0].p_purity_real_show]}
SNS-314 mesylate	+++ Aurora A, IC50: 9 nM	++ Aurora B, IC50: 31 nM	++++ Aurora C, IC50: 3 nM		{[allProObj[0].p_purity_real_show]}
Barasertib-HQPA		++++ Aurora B, IC50: 0.37 nM			{[allProObj[0].p_purity_real_show]}
Hesperadin		+ Aurora B (human), IC50: 250 nM			{[allProObj[0].p_purity_real_show]}
GSK-1070916		++++ Aurora B-INCENP, IC50: 3.5 nM	+++ Aurora C-INCENP, IC50: 6.5 nM	Tie-2,SIK	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FLT3 ↓ ↑	其他靶点	纯度
R406	✔	Syk	{[allProObj[0].p_purity_real_show]}
Go6976	✔		{[allProObj[0].p_purity_real_show]}
Quizartinib	+++ FLT3 (WT), IC50: 4.2 nM FLT3 (ITD), IC50: 1.1 nM		{[allProObj[0].p_purity_real_show]}
Gilteritinib	++++ FLT3, IC50: 0.29 nM		{[allProObj[0].p_purity_real_show]}
Amuvatinib	+ FLT3 (D835Y), IC50: 81 nM		{[allProObj[0].p_purity_real_show]}
Pacritinib	++ FLT3 (D835Y), IC50: 6 nM FLT3, IC50: 22 nM		{[allProObj[0].p_purity_real_show]}
Dovitinib	++++ FLT3, IC50: 1 nM	c-Kit	{[allProObj[0].p_purity_real_show]}
Denfivontinib	++++ FLT3 (D835Y), IC50: 0.4 nM FLT3, IC50: 0.4 nM	RET	{[allProObj[0].p_purity_real_show]}
TAK-659 HCl	++ FLT3, IC50: 4.6 nM	Syk	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FAK ↓ ↑	其他靶点	纯度
Defactinib	✔		{[allProObj[0].p_purity_real_show]}
NVP-TAE 226	++ PYK2, IC50: 3.5 nM FAK, IC50: 5.5 nM	IGF-1R,Insulin Receptor	{[allProObj[0].p_purity_real_show]}
PF-573228	+ FAK, IC50: 4 nM		{[allProObj[0].p_purity_real_show]}
Solanesol	✔		{[allProObj[0].p_purity_real_show]}
PF-431396	++ PYK2, IC50: 11 nM FAK, IC50: 2 nM		{[allProObj[0].p_purity_real_show]}
PND-1186	++++ FAK, IC50: 1.5 nM		{[allProObj[0].p_purity_real_show]}
PF-562271	++++ PYK2, IC50: 13 nM FAK, IC50: 1.5 nM		{[allProObj[0].p_purity_real_show]}
GSK2256098	++++ FAK, Ki: 0.4 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, IC50: 11 nM JAK1, Ki: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		{[allProObj[0].p_purity_real_show]}
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	{[allProObj[0].p_purity_real_show]}
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		{[allProObj[0].p_purity_real_show]}
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			{[allProObj[0].p_purity_real_show]}
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	{[allProObj[0].p_purity_real_show]}
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				{[allProObj[0].p_purity_real_show]}
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			{[allProObj[0].p_purity_real_show]}
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		{[allProObj[0].p_purity_real_show]}
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		{[allProObj[0].p_purity_real_show]}
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		{[allProObj[0].p_purity_real_show]}
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2, IC50: 0.288 nM JAK2 (V617F), Ki: 0.245 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		{[allProObj[0].p_purity_real_show]}
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		{[allProObj[0].p_purity_real_show]}
Peficitinib		✔				{[allProObj[0].p_purity_real_show]}
Go6976		✔			FLT3	{[allProObj[0].p_purity_real_show]}
AZD-1480		++++ JAK2, IC50: 0.26 nM				{[allProObj[0].p_purity_real_show]}
Fedratinib		+++ JAK2 (V617F), IC50: 3 nM JAK2, IC50: 3 nM			RET,FLT3	{[allProObj[0].p_purity_real_show]}
WP1066		+ JAK2, IC50: 2.3 μM				{[allProObj[0].p_purity_real_show]}
Curcumol		✔				{[allProObj[0].p_purity_real_show]}
AZ960		++++ JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM				{[allProObj[0].p_purity_real_show]}
GLPG0634 analog		✔				{[allProObj[0].p_purity_real_show]}
CEP-33779		++++ JAK2, IC50: 1.8 nM				{[allProObj[0].p_purity_real_show]}
FLLL32		+ JAK2, IC50: <5 μM				{[allProObj[0].p_purity_real_show]}
WHI-P154			+ JAK3, IC50: 1.8 μM		VEGFR,EGFR,Src	{[allProObj[0].p_purity_real_show]}
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		{[allProObj[0].p_purity_real_show]}
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		RET,FLT3	{[allProObj[0].p_purity_real_show]}
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			{[allProObj[0].p_purity_real_show]}
Pacritinib		++ JAK2 (V617F), IC50: 19 nM JAK2, IC50: 23 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			{[allProObj[0].p_purity_real_show]}
FM-381			++++ JAK3, IC50: 127 pM			{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	{[allProObj[0].p_purity_real_show]}
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		{[allProObj[0].p_purity_real_show]}
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			{[allProObj[0].p_purity_real_show]}
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	{[allProObj[0].p_purity_real_show]}
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,PDGFR,FGFR	{[allProObj[0].p_purity_real_show]}
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		{[allProObj[0].p_purity_real_show]}
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	{[allProObj[0].p_purity_real_show]}
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	{[allProObj[0].p_purity_real_show]}
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	{[allProObj[0].p_purity_real_show]}
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	{[allProObj[0].p_purity_real_show]}
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	{[allProObj[0].p_purity_real_show]}
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			{[allProObj[0].p_purity_real_show]}
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	{[allProObj[0].p_purity_real_show]}
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	{[allProObj[0].p_purity_real_show]}
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	{[allProObj[0].p_purity_real_show]}
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		{[allProObj[0].p_purity_real_show]}
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		{[allProObj[0].p_purity_real_show]}
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	{[allProObj[0].p_purity_real_show]}
BMS-794833		++ VEGFR2, IC50: 15 nM			{[allProObj[0].p_purity_real_show]}
SKLB1002		++ VEGFR2, IC50: 32 nM			{[allProObj[0].p_purity_real_show]}
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			{[allProObj[0].p_purity_real_show]}
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
SU 5402		++ VEGFR2, IC50: 20 nM			{[allProObj[0].p_purity_real_show]}
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	{[allProObj[0].p_purity_real_show]}
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			{[allProObj[0].p_purity_real_show]}
LY2874455		+++ VEGFR2, IC50: 7 nM			{[allProObj[0].p_purity_real_show]}
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			{[allProObj[0].p_purity_real_show]}
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			{[allProObj[0].p_purity_real_show]}
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			{[allProObj[0].p_purity_real_show]}
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	{[allProObj[0].p_purity_real_show]}
Golvatinib		++ VEGFR2, IC50: 16 nM			{[allProObj[0].p_purity_real_show]}
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	{[allProObj[0].p_purity_real_show]}
RAF265		++ VEGFR2, EC50: 30 nM			{[allProObj[0].p_purity_real_show]}
PD173074					{[allProObj[0].p_purity_real_show]}
BFH772		++++ VEGFR2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			{[allProObj[0].p_purity_real_show]}
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	{[allProObj[0].p_purity_real_show]}
SAR131675			++ VEGFR3, IC50: 23 nM		{[allProObj[0].p_purity_real_show]}
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	{[allProObj[0].p_purity_real_show]}
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

CTX-0294885 生物活性

描述	CTX-0294885 is a broad-spectrum kinase inhibitor capable of targeting 235 kinases in MDA-MB-231 cells, including all members of the AKT family, marking its utility in dissecting kinome signaling pathways for the study of diseases such as inflammation, diabetes, and cancer.
体外研究	CTX-0294885 is a valuable tool in kinome profiling experiments, capturing a wide array of kinases, and its unique ability to isolate all AKT family members highlights its potential in uncovering new aspects of kinase-related research previously unexplored with other kinase capture agents.

CTX-0294885 参考文献

[1]Zhang L, et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J Proteome Res. 2013 Jul 5;12(7):3104-16.

CTX-0294885 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.42mL

2.28mL

1.14mL

22.83mL

4.57mL

2.28mL

CTX-0294885 技术信息

CAS号	1439934-41-4
分子式	C₂₂H₂₄ClN₇O
分子量	437.925

别名
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(239.77 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

CTX-0294885 {[allProObj[0].p_purity_real_show]}

CTX-0294885 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

CTX-0294885 质控信息

CTX-0294885 生物活性

CTX-0294885 参考文献

CTX-0294885 实验方案

CTX-0294885 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CTX-0294885 {[allProObj[0].p_purity_real_show]}

CTX-0294885 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

CTX-0294885 质控信息

CTX-0294885 生物活性

CTX-0294885 参考文献

CTX-0294885 实验方案

CTX-0294885 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CTX-0294885 纯度/质量文件产品仅供科研